⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HCWB News
HCW Biologics Inc. Common Stock
HCW Biologics’ Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer
globenewswire.com
HCWB
HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company’s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer’s
globenewswire.com
HCWB
Form 8-K
sec.gov
HCWB
HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing
globenewswire.com
HCWB
HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
globenewswire.com
HCWB
Form 8-K
sec.gov
HCWB
HCW Biologics Announces Pricing of $1.5 Million Private Placement
globenewswire.com
HCWB
Form 8-K
sec.gov
HCWB
Form 8-K
sec.gov
HCWB
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
globenewswire.com
HCWB